

48. (NEW) The transformed cell of claim 11, wherein the eukaryotic cell is a SP20 cell line or an NSO cell line.

49. (NEW) The transformed cell of claim 11, wherein the eukaryotic cell is a CHO cell or a myeloma-derived cell.

B₆ 50. (NEW) The human sequence immunoglobulin of claim 13, wherein the human sequence light chain variable region comprises an amino acid sequence encoded by SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:10.

51. (NEW) The human sequence immunoglobulin of claim 13, wherein the human sequence heavy chain variable region comprises an amino acid sequence encoded by SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:9.

REMARKS

The Invention

The present invention is directed to human immunoglobulins (Ig) that bind human antigens, and the hybridomas which secrete them. In one embodiment, the human Igs of the invention bind to human CD4. The invention solves the long-standing problems of how to overcome serious obstacles to produce high affinity human immunoglobulins and human Igs for human antigens, since humans typically will not make an immune responses against self-antigens and it is clearly inappropriate to induce such autoimmune responses.


Support for the Amendment

The specification sets forth an extensive description of the invention in the new and amended claims.

Lonberg et al.
Application No.: 08/728,463

PATENT
Attorney Docket No.: 14643-009020US

Please charge the fee of \$870.00 to the undersigned's Deposit Account No. 20-1430. Please charge any additional fees or credit overpayment to the above deposit account. This petition is submitted in triplicate.



Respectfully submitted,

A handwritten signature in black ink, appearing to read "Gregory P. Einhorn".

Gregory P. Einhorn
Reg. No. 38,440

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
GPE/mcs
SF 1001504 v1